4.7 Article

Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity

Journal

CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 72, Issue 5, Pages 1327-1335

Publisher

SPRINGER
DOI: 10.1007/s00262-022-03327-w

Keywords

STING; Tumor immunity; Type I IFN; Immune checkpoint inhibitor

Ask authors/readers for more resources

STING pathway plays context-dependent roles in regulating anti-tumor immunity and response to immunotherapy. In poorly immunogenic tumor models, STING expression in non-tumor cells is crucial for productive anti-tumor immune responses. In immunogenic models, constitutive STING activation in tumor cells can partially bypass the requirement for STING-dependent activity from immune cells.
Type I interferon-mediated activation of immune cells can facilitate the generation of productive tumor antigen-specific T cell responses in solid tumors. The cGAS/STING DNA sensing pathway is a critical upstream mediator of type I interferon production and is an important regulator of anti-tumor immunity. Numerous STING pathway agonists are now being tested in clinical trials, but the effectiveness of this approach is not yet clear and a better understanding of the relative importance of this pathway in various tumor settings is needed. We have evaluated syngeneic tumor models with different baseline inflammatory states to determine the contributions of STING activity in both tumor and non-tumor cellular compartments to anti-tumor immune responses. We find that productive anti-tumor immune responses in the poorly immunogenic B16F10 model show a strong dependence on STING expression in non-tumor cells. In the immunogenic MC38 model, constitutive STING activation in tumor cells can partially bypass the requirement for STING-dependent activity from immune cells. Our findings reveal multiple, context-dependent roles for STING activity in the regulation of anti-tumor immunity and the response to immunotherapy. In preclinical models where STING is basally active, checkpoint inhibition is more likely to have a therapeutic effect and removal of STING signaling from either the tumor or the non-tumor compartment has a minimal effect. Removal of STING signaling in both, however, diminishes the efficacy derived from checkpoint therapy. Further work is needed to understand the heterogeneity of STING signaling in patients, both in tumor cells and the tumor microenvironment, and the best means of harnessing this pathway to generate anti-tumor immunity and improve therapeutic outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available